Visit
The MR CLEAN-LATE prospective, randomized study of over 500 patients with acute ischemic stroke showed that endovascular thrombectomy (EVT) provides…
On September 29, 2022, the Food and Drug Administration (FDA) approved AMX0035 for the treatment of amyotrophic lateral sclerosis (ALS),…
Current guidelines warn against the use of intravenous thrombolysis in patients with ischemic stroke and recent direct oral anticoagulant (DOAC)…
The first interim data has been published from a Phase I/II trial testing the safety and tolerability of AMT-130. If…
Myasthenia gravis (MG) is a rare disorder, exhibiting the archetypic traits of both the neuromuscular junction and autoantibody-mediated disease –…
A record-breaking study into the relationship between Epstein-Barr virus (EBV) infection and multiple sclerosis (MS) onset has revealed a 32-fold…
Insomnia is a common sleep disorder with a prevalence ranging from 5.8–20.0%1 and associated with various comorbidities and major societal…
Despite an increase in the number of treatments available for migraine, there is still an unmet need for therapies with…
Temporal lobe epilepsy (TLE) is the most common form of focal epilepsy1 and the most common type of drug-resistant epilepsy.2…
Multiple sclerosis (MS) is a long-life condition that affects the brain and spinal cord resulting in impaired vision, limb movement,…
Get the latest blog headlines delivered to your inbox.
